Prosecution Insights
Last updated: April 19, 2026

Examiner: BUCCINI, MICHELLE CALLAHAN

Tech Center 1600 • Art Units: 1654 1675

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
7
Total Applications
Interview Lift
1175
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

11.5%
§101 Eligibility
19.2%
§102 Novelty
26.9%
§103 Obviousness
30.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18240201 DIAGNOSIS AND TREATMENT OF PRIMARY GRAFT DYSFUNCTION FOLLOWING LUNG TRANSPLANT Non-Final OA Northwestern University
18460810 METHOD FOR PRODUCING PROTEIN HAVING SUPRAMOLECULAR STRUCTURE IN WHICH BIOACTIVE SUBSTANCE IS ENCAPSULATED Non-Final OA AJINOMOTO CO., INC.
18381081 NON-HLA RESTRICTED T CELL VACCINE FOR TCR GAMMA ALTERNATE READING FRAME PROTEIN (TARP) PROTEIN EXPRESSING CANCERS Non-Final OA PDS BIOTECHNOLOGY CORPORATION
18357160 METHOD FOR TREATING CANCER AND INFLAMMATORY DISEASES USING STEM CELL- DERIVED EXTRACELLULAR VESICLES COMPRISING SIRP Non-Final OA SHIFTBIO INC.
17924511 METHOD AND SYSTEM FOR DIAGNOSING CENTRAL NERVOUS SYSTEM DISEASE USING MULTIPLE BIOMARKERS IN PERIPHERAL BODY FLUID Non-Final OA XY EVERGREEN TECHNOLOGY COMPANY

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month